Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

t sales.

Research and development costs for the full year 2012 were $45.9 million compared with $61.9 million for the full year 2011.  This decrease in expense results principally from a reduction in 2012 of activities related to the development of a larger scale XIAFLEX production process and the completion of the phase III XIAFLEX clinical trials for Peyronie's disease in third quarter 2012, partially offset by spending in 2012 related to the Dupuytren's multi-cord study and new indications for XIAFLEX.

Selling, general and administrative expenses totaled $185.5 million for the year ended December 31, 2012, compared with $179.9 million for the year-ago period.  This increase was primarily due to marketing spending for Dupuytren's and for the potential future launch of Peyronie's, increased business development and legal expenses, and costs incurred in 2012 related to the relocation of the company's headquarters, offset in part by costs incurred in 2011 related to management changes.

Auxilium reported net income of $85.9 million, or $1.74 per share, fully diluted, for the full year 2012, compared to a net loss of $(32.9) million, or $(0.69) per share, fully diluted, for the full year 2011.  The increase in net income was primarily related to $85.2 million recorded as a result of the previously announced agreement to mutually terminate the Company's European collaboration with Pfizer.  Net income for 2012 includes total stock-based compensation expense of $15.0 million, compared to $17.3 million included in the net loss for the full year 2011.

Accounting for Pfizer TerminationAs part of the collaboration agreement we entered into with Pfizer in 2008, we have received up front and milestone cash payments from Pfizer.  Our agreement with our licensor for XIAFLEX required that we pay a portion of these amounts to them.  These amounts were recorded as deferred revenues and deferred costs, respectively, on our b
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... be the nation,s next "Strontium Valley"? The University of Pittsburgh ... the National Science Foundation and the Nanoelectronics Research Initiative (NRI) ... kind of computer out of the lab and into the ... Levy, a professor of physics and astronomy in Pitt,s School ...
... 19, 2011 Reportlinker.com announces that a ... its catalogue: Established and ... http://www.reportlinker.com/p0618133/Established-and-Emerging-Biotech-Clusters.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology There has ... clusters of biotechnology companies and related organizations. ...
... HAYWARD, Calif., Sept. 19, 2011 OptiScan Biomedical ... systems for use in intensive care units (ICU), ... Glucose Monitoring System has received CE Mark certification ... Mark certifies that the OptiScanner has met all ...
Cached Biology Technology:Post-silicon computing 2Post-silicon computing 3Post-silicon computing 4Established and Emerging Biotech Clusters 2Established and Emerging Biotech Clusters 3Established and Emerging Biotech Clusters 4Established and Emerging Biotech Clusters 5Established and Emerging Biotech Clusters 6Established and Emerging Biotech Clusters 7Established and Emerging Biotech Clusters 8OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 2OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 3OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 4
(Date:4/17/2014)... way the immune system may fight cancers and viral ... cells to treat illness. , The research, in mice, ... "neighborhood police" specialized squads of defenders that patrol ... entire city, the body. , Scientists at Washington University ... the liver, skin and uterus each has dedicated immune ...
(Date:4/17/2014)... domestication derive from Charles Darwin, whose ideas in ... during the 19th century, a period when landowners ... is from Darwin that we inherit the ideas ... wild species and total human control over breeding ... this industrial setting has been applied too broadly ...
(Date:4/16/2014)... have identified a new syndrome called "osteosarcopenic obesity" that ... with obesity. , "It used to be the thinking ... would be because the bones were supporting more weight," ... at Florida State. "But, that,s only true to a ...
Breaking Biology News(10 mins):Some immune cells defend only 1 organ 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2
... GAINESVILLE, Fla. Hit-and-run attacks by sharks can be ... by the unique chomp they put on their victims, ... expert. In a method analogous to analyzing human ... bites to the jaws and teeth of the powerful ...
... Charles Darwin it was an ,abominable mystery, and it is a ... did flowering plants evolve and how did they come to dominate ... reveals the evolutionary trigger which led to early flowering plants ... subsequent boom and abundance. The study, by Dr Tim Brodribb ...
... The first comprehensive review of the state of Antarctica,s ... is published this week (Tuesday 1 December) by the ... - Antarctic Climate Change and the Environment presents ... for future scientific research, and addresses the urgent questions ...
Cached Biology News:New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3How did flowering plants evolve to dominate Earth? 2First comprehensive review of the state of Antarctica's climate 2
... is formulated for covering tissue sections and cell preparations immunohistochemically ... products. , ... Application: Vision ... AEC that require an aqueous mounting medium, or those that ...
... Target Retrieval Solution, High pH ... heat-induced target retrievel prior to immunohistochemical staining ... paraffin-embedded tissue sections mounted on glass slides. ... pH, 9.9, is especially effective. It should ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... High pH, Concentrated x 10 This ... target retrievel prior to immunohistochemical staining procedures. ... tissue sections mounted on glass slides. For ... 9.9, is especially effective. It should be ...
Biology Products: